EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male Subjects

Jianxin Wang, Kai Gu, Mingxuan Zhang, Miao Yu, Pei Zhao, Jing Yu, Xiaohong Guo, Yating Bai, Jie Liu, Xiaoli Wang, Xiaolai Yang

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70121 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Jianxin Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of pharmacy, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China. Hauptthemen laut MEDLINE: Drugs, Generic, Phenylthiohydantoin. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shandong New Time Pharmaceutical Co., Ltd., Practice and Research on the Construction of a Technical Platform for New Drug Clinical Evaluation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enzalutamide is an oral second‐generation androgen receptor inhibitor used for advanced prostate cancer. This study evaluated the pharmacokinetics (PK), bioequivalence (BE), and safety of a newly developed generic enzalutamide soft capsule (test) compared with the reference product (XTANDI) in healthy Chinese adults under fasting and fed conditions. A single‐center, randomized, open‐label, two‐period, two‐sequence, crossover study was conducted in 72 male participants (36 fasting and 36 fed). Each participant received a single 40‐mg dose of test or reference formulation, separated by a 34‐day washout. Blood samples were collected up to 72 h post‐dose. PK parameters (C max and AUC 0‐72 h ) were calculated using non‐compartmental analysis. BE was assessed by 90% confidence intervals (CIs) of geometric mean ratios (GMRs). Safety was monitored throughout the study. In both fasting and fed conditions, the 90% CIs of GMRs for C max and AUC 0‐72 h were within the predefined 80%–125% BE range. Both formulations exhibited a favorable single‐dose safety profile, with no serious adverse events reported. The test enzalutamide soft capsule is bioequivalent to the reference product in healthy Chinese volunteers, demonstrating similar PK profiles and safety. This study provides population‐specific PK evidence supporting the clinical use of the generic formulation in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, GenericPhenylthiohydantoinAdultHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveBenzamidesCapsulesChinaCross-Over StudiesFastingHealthy VolunteersNitrilesTherapeutic Equivalency

Stichwörter der Autor:innen

bioequivalenceenzalutamide soft capsulespharmacokineticssafety

Substanzen

BenzamidesCapsulesDrugs, GenericenzalutamideNitrilesPhenylthiohydantoin

Autor:innen und Institutionen

  • School of pharmacy, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
  • Department of Pharmacy, Gansu Provincial People's Hospital, Lanzhou, Gansu Province, China.
  • Faculty of Health Sciences (FHS), University of Macau, Taipa, Macau SAR, China.

Förderung

  • Shandong New Time Pharmaceutical Co., Ltd.
  • Practice and Research on the Construction of a Technical Platform for New Drug Clinical Evaluation

Zitieren

APA

Wang, J., Gu, K., Zhang, M., Yu, M., Zhao, P., Yu, J., Guo, X., Bai, Y., Liu, J., Wang, X., & Yang, X. (2026). A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70121

Vancouver

Wang J, Gu K, Zhang M, Yu M, Zhao P, Yu J, et al. A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male Subjects. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70121

BibTeX
@article{Wang2026,
  author = {Wang, Jianxin and Gu, Kai and Zhang, Mingxuan and Yu, Miao and Zhao, Pei and Yu, Jing and Guo, Xiaohong and Bai, Yating and Liu, Jie and Wang, Xiaoli and Yang, Xiaolai},
  title = {A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male Subjects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70121}
}
Kostenlos starten →